Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
University of Minnesota is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Antoinette Moran, MD, the TrialNet team at University of Minnesota is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Mary Greeley Medical Center Diabetes Center
1111 Duff Ave, Ames, IA 50010
Central Iowa Hospital Corporation
1215 Pleasant St., Ste 300, Des Moines, IA 50309
Sanford Research - Fargo
737 Broadway N, Fargo, ND 58122
Esse Health, Pediatric Endocrinology
1125 Graham Rd, Building C, Ste 1350, Florissant, MO 63031
Altru Health System - Research Dept.
860 South Columbia Road, Grand Folks, ND 58201
University of Iowa, Childrens Hospital of Iowa
25 S Grand Avenue 2160 ML, Iowa City, IA 52242
Regional Health Clinical Research
735 Meade Street, Rapid City, SD 57701
Sanford Childrens Specialty Clinic
1018 West 18th Street, Sioux Falls, SD 57104
Childrens Hospital & Clinics of Minnesota
345 N. Smith Ave MS70-404, St. Paul, MN 55102
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.
We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.
Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.